(a) In generalNot later than 2 years after December 13, 2016, the Secretary, in consultation with the National Institute of Standards and Technology and stakeholders (including regenerative medicine and advanced therapies manufacturers and clinical trial sponsors, contract manufacturers, academic institutions, practicing clinicians, regenerative medicine and advanced therapies industry organizations, and standard setting organizations), shall facilitate an effort to coordinate and prioritize the development of standards and consensus definition of terms, through a public process, to support, through regulatory predictability, the development, evaluation, and review of regenerative medicine therapies and regenerative advanced therapies, including with respect to the manufacturing processes and controls of such products.
(b) Activities(1) In generalIn carrying out this section, the Secretary shall continue to—(A) identify opportunities to help advance the development of regenerative medicine therapies and regenerative advanced therapies;
(B) identify opportunities for the development of laboratory regulatory science research and documentary standards that the Secretary determines would help support the development, evaluation, and review of regenerative medicine therapies and regenerative advanced therapies through regulatory predictability; and
(C) work with stakeholders, such as those described in subsection (a), as appropriate, in the development of such standards.
(2) Regulations and guidanceNot later than 1 year after the development of standards as described in subsection (a), the Secretary shall review relevant regulations and guidance and, through a public process, update such regulations and guidance as the Secretary determines appropriate.
(c) DefinitionsFor purposes of this section, the terms “regenerative medicine therapy” and “regenerative advanced therapy” have the meanings given such terms in section 356(g) of this title.
Structure US Code
CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT
SUBCHAPTER V— DRUGS AND DEVICES
§ 351. Adulterated drugs and devices
§ 352. Misbranded drugs and devices
§ 353. Exemptions and consideration for certain drugs, devices, and biological products
§ 353a–1. Enhanced communication
§ 353b. Outsourcing facilities
§ 353c. Prereview of television advertisements
§ 353d. Process to update labeling for certain generic drugs
§ 354. Veterinary feed directive drugs
§ 355–1. Risk evaluation and mitigation strategies
§ 355–2. Actions for delays of generic drugs and biosimilar biological products
§ 355a. Pediatric studies of drugs
§ 355b. Adverse-event reporting
§ 355c. Research into pediatric uses for drugs and biological products
§ 355e. Pharmaceutical security
§ 355f. Extension of exclusivity period for new qualified infectious disease products
§ 355g. Utilizing real world evidence
§ 356. Expedited approval of drugs for serious or life-threatening diseases or conditions
§ 356–1. Accelerated approval of priority countermeasures
§ 356–2. Accelerated approval Council
§ 356b. Reports of postmarketing studies
§ 356c. Discontinuance or interruption in the production of life-saving drugs
§ 356c–1. Annual reporting on drug shortages
§ 356d. Coordination; task force and strategic plan
§ 356f. Hospital repackaging of drugs in shortage
§ 356g. Standards for regenerative medicine and regenerative advanced therapies
§ 356h. Competitive generic therapies
§ 356i. Prompt reports of marketing status
§ 356j. Discontinuance or interruption in the production of medical devices
§ 356l. Advanced manufacturing technologies designation program
§ 357. Qualification of drug development tools
§ 358. Authority to designate official names
§ 359. Nonapplicability of subchapter to cosmetics
§ 360. Registration of producers of drugs or devices
§ 360a. Clinical trial guidance for antibiotic drugs
§ 360a–2. Susceptibility test interpretive criteria for microorganisms
§ 360b–1. Priority zoonotic animal drugs
§ 360c. Classification of devices intended for human use
§ 360e–1. Pediatric uses of devices
§ 360e–3. Breakthrough devices
§ 360e–4. Predetermined change control plans for devices
§ 360g–1. Agency documentation and review of significant decisions regarding devices
§ 360g–2. Third party data transparency
§ 360h. Notification and other remedies
§ 360h–1. Program to improve the device recall system
§ 360i. Records and reports on devices
§ 360j. General provisions respecting control of devices intended for human use
§ 360k. State and local requirements respecting devices
§ 360l. Postmarket surveillance
§ 360n. Priority review to encourage treatments for tropical diseases
§ 360n–1. Priority review for qualified infectious disease products